SPRB Latest Press Releases

-- November 2, 2026 --

Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference Business Wire 4:05 PM

-- October 15, 2026 --

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference Business Wire 4:05 PM

-- October 8, 2026 --

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting Business Wire 4:05 PM

-- September 8, 2026 --

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Business Wire 4:05 PM

-- August 26, 2026 --

Spruce Biosciences Announces Launch of MPS3BStudy.com Business Wire 8:00 AM

-- August 24, 2026 --

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 Business Wire 8:00 AM

-- August 12, 2026 --

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Business Wire 9:00 AM

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences Business Wire 8:00 AM

-- August 3, 2026 --

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development Business Wire 8:00 AM

-- July 27, 2026 --

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer Business Wire 8:00 AM

-- July 8, 2026 --

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit Business Wire 4:01 PM

-- June 29, 2026 --

Spruce Biosciences Joins the Russell 3000 Index Business Wire 8:00 AM

-- June 22, 2026 --

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs Business Wire 8:00 AM

-- June 15, 2026 --

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller Business Wire 8:00 AM

-- June 8, 2026 --

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium Business Wire 4:05 PM

Market Data Delayed 15 Minutes